Vetr upgraded shares of Gilead Sciences, Inc. (NASDAQ:GILD) from a buy rating to a strong-buy rating in a research note published on Friday morning. They currently have $91.98 price target on the biopharmaceutical company’s stock.

A number of other analysts have also recently issued reports on the stock. Barclays PLC restated an overweight rating and set a $90.00 target price on shares of Gilead Sciences in a research note on Wednesday. Morgan Stanley restated an equal weight rating and set a $83.00 target price (up previously from $77.00) on shares of Gilead Sciences in a research note on Friday, October 6th. Leerink Swann raised their target price on shares of Gilead Sciences from $87.00 to $89.00 and gave the stock a market perform rating in a research note on Thursday, October 5th. CIBC assumed coverage on shares of Gilead Sciences in a research note on Thursday, October 5th. They set a market perform rating for the company. Finally, Oppenheimer Holdings, Inc. assumed coverage on shares of Gilead Sciences in a research note on Thursday, October 5th. They set a market perform rating for the company. Twelve equities research analysts have rated the stock with a hold rating, twenty have assigned a buy rating and one has given a strong buy rating to the company. The stock has an average rating of Buy and an average target price of $85.96.

Gilead Sciences (NASDAQ:GILD) traded down 0.16% on Friday, hitting $81.17. 5,682,947 shares of the stock traded hands. The stock has a market cap of $106.00 billion, a price-to-earnings ratio of 8.82 and a beta of 1.14. The firm’s 50 day moving average is $82.23 and its 200 day moving average is $72.17. Gilead Sciences has a 52 week low of $63.76 and a 52 week high of $86.27.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.11 by $0.45. The company had revenue of $7.14 billion during the quarter, compared to analysts’ expectations of $6.35 billion. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. Gilead Sciences’s quarterly revenue was down 8.2% compared to the same quarter last year. During the same quarter last year, the company posted $3.08 EPS. Equities analysts anticipate that Gilead Sciences will post $8.75 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This article was first reported by Watch List News and is owned by of Watch List News. If you are accessing this article on another website, it was illegally copied and reposted in violation of United States and international copyright law. The legal version of this article can be read at https://www.watchlistnews.com/gilead-sciences-inc-gild-upgraded-to-strong-buy-by-vetr-inc/1631147.html.

The business also recently declared a quarterly dividend, which was paid on Thursday, September 28th. Stockholders of record on Friday, September 15th were paid a $0.52 dividend. The ex-dividend date was Thursday, September 14th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.56%. Gilead Sciences’s payout ratio is currently 22.58%.

In related news, CFO Robin L. Washington sold 51,820 shares of Gilead Sciences stock in a transaction that occurred on Thursday, September 7th. The shares were sold at an average price of $85.00, for a total transaction of $4,404,700.00. Following the sale, the chief financial officer now directly owns 43,352 shares in the company, valued at approximately $3,684,920. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider John C. Martin sold 73,333 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, August 1st. The stock was sold at an average price of $75.86, for a total transaction of $5,563,041.38. Following the sale, the insider now owns 3,199,969 shares in the company, valued at $242,749,648.34. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 486,819 shares of company stock worth $39,298,919. 1.30% of the stock is currently owned by corporate insiders.

A number of large investors have recently bought and sold shares of the stock. Keel Point LLC boosted its position in Gilead Sciences by 0.4% during the 1st quarter. Keel Point LLC now owns 3,111 shares of the biopharmaceutical company’s stock worth $211,000 after buying an additional 11 shares during the period. Paradigm Financial Advisors LLC boosted its position in Gilead Sciences by 0.3% during the 2nd quarter. Paradigm Financial Advisors LLC now owns 8,723 shares of the biopharmaceutical company’s stock worth $617,000 after buying an additional 26 shares during the period. West Oak Capital LLC boosted its position in Gilead Sciences by 0.7% during the 2nd quarter. West Oak Capital LLC now owns 4,666 shares of the biopharmaceutical company’s stock worth $330,000 after buying an additional 32 shares during the period. First Heartland Consultants Inc. boosted its position in Gilead Sciences by 0.4% during the 2nd quarter. First Heartland Consultants Inc. now owns 8,927 shares of the biopharmaceutical company’s stock worth $632,000 after buying an additional 39 shares during the period. Finally, Princeton Portfolio Strategies Group LLC boosted its position in Gilead Sciences by 0.4% during the 2nd quarter. Princeton Portfolio Strategies Group LLC now owns 9,766 shares of the biopharmaceutical company’s stock worth $691,000 after buying an additional 41 shares during the period. Institutional investors and hedge funds own 73.98% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.